What is Gentronix?
Gentronix operates as a specialized Contract Research Organization (CRO) with a deep-rooted history spanning over 25 years. The company provides essential predictive toxicology products and services, primarily serving the global chemical industry. Its core competencies lie in genotoxicity testing, where it offers both regulatory-grade studies and innovative early-stage screening assays. By providing high-quality scientific data, Gentronix enables its clients to mitigate risks early in the product development lifecycle, ensuring compliance with stringent international safety standards. The firm's market position is defined by its technical expertise and its commitment to streamlining the path to regulatory approval for complex chemical compounds.
How much funding has Gentronix raised?
Gentronix has raised a total of $939K across 1 funding round:
Unspecified
$939K
Unspecified (2021): $939K with participation from Mercia Group
Key Investors in Gentronix
Mercia Group
Mercia Group is a diversified firm providing professional training, regulatory compliance support, and operational solutions, primarily focused on the accounting and financial services sectors in the UK and Ireland.
What's next for Gentronix?
Looking ahead, the strategic deployment of this capital will likely focus on scaling the company's laboratory infrastructure and enhancing its digital screening platforms. As global regulatory bodies continue to tighten requirements for chemical safety, the demand for high-fidelity toxicology data is expected to rise, providing Gentronix with a clear growth trajectory. The company is poised to capitalize on these industry shifts by investing in advanced analytical technologies and expanding its service portfolio to address emerging toxicological challenges. This strategic growth phase will be instrumental in maintaining the firm's competitive edge as it continues to support global clients in achieving safe and compliant product commercialization.
See full Gentronix company page
